Development strategies of prophylactic vaccines for older adults
10.13200/j.cnki.cjb.003938
- VernacularTitle:老年人预防性疫苗研发策略
- Author:
YAN Xiaojin
- Publication Type:Journal Article
- Keywords:
Vaccine;
Older adults;
Infectious disease;
Immunosenescence;
Adjuvant
- From:
Chinese Journal of Biologicals
2023;36(7):883-891
- CountryChina
- Language:Chinese
-
Abstract:
The vaccination of older adults is receiving increasing attention from the whole society.The majority of deaths caused by Coronavirus Disease 2019(COVID-19) are older adults,especially those with underlying diseases.Severe acute respiratory symptom coronavirus 2(SARS-CoV-2) vaccines have proved to have a significant protection against severe disease and death in the older adults.At present,the vaccination coverage rate of older adults in China is insufficient,and the main obstacles from the audience include the lack of popular vaccination education and willingness to vaccination,while there are also problems from vaccine providers,such as the lack of vaccines suitable for the elderly and the high price of vaccine.This paper summarized the market status and research progress of vaccines for the older adults in China,and analyzed the effects of underlying diseases,immune aging and previous infection history or vaccination history of older adults on the safety and effectiveness of the vaccines.The strategies of vaccine development for the older adults were discussed in terms of the application of novel adjuvants to improve immunogenicity,optimization of vaccine preclinical study evaluation criteria based on the immune system characteristics of older adults,focus on enhancing cellular immune response,and development of vaccines for oral and inhalation vaccination.
